BioXcel Therapeutics (BTAI) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
UPDATE: SunTrust Starts BioXcel Therapeutics (BTAI) at Buy
November 12, 2019 4:31 AM EST(Updated - November 12, 2019 7:26 AM EST)
(updated to add analyst comments)
SunTrust analyst Robyn Karnauskas initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Buy rating and a price target of $24.00.
The analyst commented, "BioXcel's lead asset BXCL501 is in... More
